Functional autoantibodies in systemic sclerosis (Q38570322)

4 September 2017

Functional autoantibodies in systemic sclerosis (English)

1 reference

4 September 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Elise Siegert

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Jeannine Günther

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jakob M van Laar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gabriela Riemekasten

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

21 August 2015

1 reference

Seminars in Immunopathology

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

529-542

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292621%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00281-015-0513-5

1 June 2020

exact match

0 references

cites work

Autoantibodies in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Functional autoantibodies, a new paradigm in autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Solving the puzzle of autoimmunity: critical questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Genetics and autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Estrogen alters thresholds for B cell apoptosis and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Human parvovirus B19 infection and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

The role of infections in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Infections and autoimmunity--friends or foes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Infectome: a platform to trace infectious triggers of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Environment, autoantibodies, and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autoantibodies in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

The role of autoantibodies in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Thyrotropin Receptor Autoantibodies Induce Human Thyroid Cell Growth and c-fosActivation*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Activating autoantibodies and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Molecular mechanisms of anti-G-protein-coupled receptor autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Seven-transmembrane receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Pathogenic autoantibodies in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

B cell selection and susceptibility to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Estrogen receptors regulate innate immune cells and signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Estrogen receptor profiles in human peripheral blood lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autoantibodies to estrogen receptor α in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Is preeclampsia an autoimmune disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Involvement of functional autoantibodies against vascular receptors in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Noncanonical transforming growth factor beta signaling in scleroderma fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Complex regulation of pulmonary inflammation and fibrosis by CCL18

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Antibody-mediated gastrointestinal dysmotility in scleroderma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients' sera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Pathogenesis of scleroderma. Collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Competence and competition: the challenge of becoming a long-lived plasma cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Long-lived plasma cells and their contribution to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Immunoadsorption for connective tissue disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Aptamer binding and neutralization of β1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

The patent situation concerning the treatment of diseases associated with autoantibodies directed against G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-015-0513-5

Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis

21 January 2018

1 reference

12 December 2020

Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis.

1 reference

12 December 2020

The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

1 reference

12 December 2020

Auto-immunization in thyroid diseases

1 reference

12 December 2020

Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus

1 reference

12 December 2020

In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease

1 reference

12 December 2020

Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil

1 reference

12 December 2020

DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients

1 reference

12 December 2020

Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension

1 reference

12 December 2020

Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology

1 reference

12 December 2020

Influence of anti-beta-receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus

1 reference

12 December 2020

Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis

1 reference

12 December 2020

The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts

1 reference

12 December 2020

Human anti-estrogen receptor antibodies: assay, characterization, and age- and sex-related differences

1 reference

12 December 2020

Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome

1 reference

12 December 2020

Autoantibodies to nuclear lamins and to intermediate filament proteins: natural, pathologic or pathogenic?

1 reference

12 December 2020

Anti-TSH receptor antibodies in Graves' disease modulate the kinetic behaviour of autologous thyroid TSH receptors. Evidence of the IgG-induced cross-linkage of autologous TSH receptors

1 reference

12 December 2020

Both TSH and thyroid-stimulating antibody of Graves' disease bind to an Mr 197,000 holoreceptor

1 reference

12 December 2020

Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis

1 reference

12 December 2020

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

12 December 2020

Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis

1 reference

12 December 2020

Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy

1 reference

12 December 2020

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

1 reference

12 December 2020

The epidemiology of Sjögren's syndrome

1 reference

12 December 2020

Discussion on the importance of auto-antibody disease in clinical medicine; introduction: renal and thyroid diseases

1 reference

12 December 2020

Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis

1 reference

12 December 2020